Cabergoline 0.5mg x 30ml

Description

Cabergoline 0.5mg x 30ml

The the early 1980’s, cabergoline was invented by an Italian drug company called Farmitalia Carlo Erba, which is now owned by Pfizer. Scientists discovered the drug while experimenting with ergot (fungus) alkaloids. The FDA approved the drug in 1996, and it went generic in 2005 after its patent expired in the US. Cabergoline is used in clinical and research settings for different types of medical problems that occur when too much of the hormone prolactin is produced. It can potentially be used for menstrual problems, fertility and sexual problems in men and women, and increase testosterone. Cabergoline is an ergot derivative and a potent dopamine D2 receptor agonist.  The secretion of prolactin by the anterior pituitary is mainly under hypothalamic inhibitory control, likely exerted through release of dopamine by tuberoinfundibular neurons. Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. Results of in vitro studies demonstrate that cabergoline exerts a direct inhibitory effect on the secretion of prolactin by rat pituitary lactotrophs. Cabergoline decreased serum prolactin levels in reserpinized rats. Receptor-binding studies indicate that Cabergoline has low affinity for dopamine D1, α1- and α2-adrenergic, and 5-HT1- and 5-HT2-serotonin receptors. The chemical name for Cabergoline is 1-[(6-allylergolin-8ß-yl)-carbonyl]-1-[3-(dimethylamino) propyl]-3-ethylurea.

Formula:                C26H37N5O2

Molar Mass:          451.6 g/mol